Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Endocrine ; 80(3): 529-540, 2023 06.
Article de Anglais | MEDLINE | ID: mdl-37029854

RÉSUMÉ

BACKGROUND AND AIMS: The gut microbiome is associated with obesity, mainly mediated by bacteria-produced short-chain fatty acids (SCFAs). It is unknown how SCFA concentrations are associated with the phenotypes metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUNW), metabolically healthy obese/overweight (MHO), and metabolically unhealthy obese/overweight (MUO). We compared plasma and fecal SCFA concentrations among adult women categorized according to the metabolic phenotypes mentioned above and examined associations between SCFA and adiposity and components of energy and glucose homeostasis. METHODS: This was a cross-sectional study involving 111 participants. Body composition was assessed by DEXA. Energy and glycemic homeostasis were assessed by the standard mixed-meal tolerance test coupled with indirect calorimetry. SCFAs were quantified by gas chromatography and mass spectrometry. RESULTS: Only plasma propionate was increased in the MHNW phenotype compared to the MHO and MUO phenotypes [p < 0.05]. Fecal propionate and butyrate concentrations and plasma propionate concentrations were inversely associated with total and visceral adiposity [p < 0.05]. Fecal and plasma SCFA concentrations were associated with reduced glucose, insulin and HbA1c levels, increased fasting and postprandial GLP-1 levels; and more preserved beta-cell function [p < 0.05]. Fecal and plasma SCFA concentrations were positively correlated with resting energy expenditure and lipid oxidation rate and inversely correlated with the oxidation rate of carbohydrates [p < 0.05]. CONCLUSION: These findings reinforce the concept that fecal and plasma SCFA concentrations are linked to specific components of energy and glucose homeostasis; and body adiposity. However, it was not possible to discriminate the different metabolic phenotypes of adiposity based on the determination of fecal SCFA concentrations.


Sujet(s)
Syndrome métabolique X , Nutritionnistes , Femelle , Humains , Surpoids/métabolisme , Adiposité , Propionates , Études transversales , Obésité/métabolisme , Acides gras volatils , Phénotype , Homéostasie , Glucose , Indice de masse corporelle , Syndrome métabolique X/métabolisme
2.
Sci Adv ; 8(30): eabm7355, 2022 07 29.
Article de Anglais | MEDLINE | ID: mdl-35905178

RÉSUMÉ

Hypothalamic interleukin-6 (IL6) exerts a broad metabolic control. Here, we demonstrated that IL6 activates the ERK1/2 pathway in the ventromedial hypothalamus (VMH), stimulating AMPK/ACC signaling and fatty acid oxidation in mouse skeletal muscle. Bioinformatics analysis revealed that the hypothalamic IL6/ERK1/2 axis is closely associated with fatty acid oxidation- and mitochondrial-related genes in the skeletal muscle of isogenic BXD mouse strains and humans. We showed that the hypothalamic IL6/ERK1/2 pathway requires the α2-adrenergic pathway to modify fatty acid skeletal muscle metabolism. To address the physiological relevance of these findings, we demonstrated that this neuromuscular circuit is required to underpin AMPK/ACC signaling activation and fatty acid oxidation after exercise. Last, the selective down-regulation of IL6 receptor in VMH abolished the effects of exercise to sustain AMPK and ACC phosphorylation and fatty acid oxidation in the muscle after exercise. Together, these data demonstrated that the IL6/ERK axis in VMH controls fatty acid metabolism in the skeletal muscle.


Sujet(s)
AMP-Activated Protein Kinases , Interleukine-6 , AMP-Activated Protein Kinases/génétique , AMP-Activated Protein Kinases/métabolisme , Animaux , Acides gras/métabolisme , Humains , Hypothalamus/métabolisme , Interleukine-6/génétique , Interleukine-6/métabolisme , Souris , Muscles squelettiques/métabolisme , Oxydoréduction
3.
J Nutr Biochem ; 65: 93-100, 2019 03.
Article de Anglais | MEDLINE | ID: mdl-30660958

RÉSUMÉ

Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease characterized by a non-fully reversible airflow limitation comprising chronic bronchitis and pulmonary emphysema both being induced by cigarette smoke (CS) exposure. Lycopene has shown antioxidant and anti-inflammatory properties that can prevent acute lung inflammation and emphysema. We hypothesized that administration with lycopene would repair lung damage in emphysema caused by CS exposure. Mice were administered with two different doses of lycopene (25 or 50 mg/kg/day, diluted in sunflower oil by orogastric gavage) and then exposed to 60 days of CS or not (CG). Lycopene promoted a reduction in the number of total leukocytes and it improved pulmonary emphysema. Lycopene was able to minimize redox processes by decreasing lipid peroxidation and DNA damage, and by having an increase in the activities of SOD, CAT and GSH content. Furthermore, it decreased levels of TNF-α, IFN-γ and IL-10. In addition, it was able to decrease MPO activity and nitrite content. In conclusion, our data elucidated the role of lycopene as an antioxidant and anti-inflammatory agent in mice exposed to CS.


Sujet(s)
Fumer des cigarettes/physiopathologie , Lycopène/pharmacologie , Emphysème pulmonaire/traitement médicamenteux , Animaux , Antioxydants/métabolisme , Liquide de lavage bronchoalvéolaire/cytologie , Cytokines/métabolisme , Altération de l'ADN/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Hématocrite , Peroxydation lipidique/effets des médicaments et des substances chimiques , Mâle , Souris de lignée C57BL , Nitrites/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Emphysème pulmonaire/induit chimiquement , Emphysème pulmonaire/anatomopathologie
4.
Int Immunopharmacol ; 54: 275-279, 2018 Jan.
Article de Anglais | MEDLINE | ID: mdl-29174925

RÉSUMÉ

The alveolar surfactant, which composition consists of a unique and complex mixture of lipids and proteins, has immunomodulatory action. This study aimed to evaluate the effects of exogenous surfactant on pulmonary inflammatory response in mice exposed to cigarette smoke (CS). Twenty-four mice C57BL/6 were divided into four groups: control group exposed to ambient air (CG); surfactant treated group (SG); CS exposed group (CSG) and CS exposed group treated with surfactant (CSSG). For five days, CSG and CSSG were exposed to 12 commercial cigarettes/day and SG and CSSG received the surfactant by intranasal instillation. At the end of the experiment, the animals were euthanatized for the collection of bronchoalveolar lavage fluid (BALF) and lungs. The total number of leukocytes in BALF increased in CSG compared to CG, however, there was a decrease in CSSG compared to CSG. There was an increase in lipid peroxidation in SG and CSG compared to CG while there was a decrease in CSSG compared to CSG. Regarding the antioxidant enzymes, the catalase (CAT) activity increased in all groups compared to CG and the superoxide dismutase (SOD) activity decreased in CSG compared to the CG and SG. There was an increase in TNF in SG, CSG and CSSG compared to CG. There was an increase in IL-17 in CSSG compared to CG. There was an increase in CCL5 in SG and CSSG compared to CG. Therefore, our results demonstrated that the administration of exogenous surfactant was able to decrease the oxidative processes in the lungs of mice induced by short-term exposure to CS.


Sujet(s)
Liquide de lavage bronchoalvéolaire/immunologie , Fumer des cigarettes/effets indésirables , Leucocytes/immunologie , Poumon/anatomopathologie , Surfactants pulmonaires/administration et posologie , Animaux , Catalase/métabolisme , Interleukine-17/métabolisme , Peroxydation lipidique , Poumon/métabolisme , Mâle , Souris , Souris de lignée C57BL , Stress oxydatif , Superoxide dismutase/métabolisme , Facteur de nécrose tumorale alpha/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE